Show Search Form
registered interest | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
date | ||||||||||||||||||||||||||||||||||
answering body |
|
|||||||||||||||||||||||||||||||||
answering dept id | 17 | |||||||||||||||||||||||||||||||||
answering dept short name | Health and Social Care | |||||||||||||||||||||||||||||||||
answering dept sort name | Health and Social Care | |||||||||||||||||||||||||||||||||
hansard heading | Voluntary Scheme for Branded Medicines Pricing and Access | |||||||||||||||||||||||||||||||||
house id | 2 | |||||||||||||||||||||||||||||||||
legislature |
|
|||||||||||||||||||||||||||||||||
question text | To ask His Majesty's Government what assessment they have made of the findings of the report by The Association of the British Pharmaceutical Industry False economy? How NHS medicine procurement threatens the UK’s Life Sciences growth engine, published on 23 February, that the continued current high rebate rates under the voluntary and statutory schemes for branded medicines during the next five years would mean foregoing £50 billion in GDP and £17.9 billion in tax revenues as a result of lost research and development investment; and what are their estimates of the value of the potential lost investment in this sector. | |||||||||||||||||||||||||||||||||
tabling member printed |
|
|||||||||||||||||||||||||||||||||
uin | HL6287 | |||||||||||||||||||||||||||||||||
answer |
|
|||||||||||||||||||||||||||||||||
tabling member |
|
registered interest | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
date | |||||||||||||||||||||||||||||||
answering body |
|
||||||||||||||||||||||||||||||
answering dept id | 17 | ||||||||||||||||||||||||||||||
answering dept short name | Health and Social Care | ||||||||||||||||||||||||||||||
answering dept sort name | Health and Social Care | ||||||||||||||||||||||||||||||
hansard heading | Tixagevimab/cilgavimab | ||||||||||||||||||||||||||||||
house id | 2 | ||||||||||||||||||||||||||||||
legislature |
|
||||||||||||||||||||||||||||||
question text | To ask Her Majesty's Government how much Evusheld monoclonal antibody treatment they have secured; and when this treatment will be available to the clinically vulnerable in the UK. | ||||||||||||||||||||||||||||||
tabling member printed |
|
||||||||||||||||||||||||||||||
uin | HL6287 | ||||||||||||||||||||||||||||||
answer |
|
||||||||||||||||||||||||||||||
tabling member |
|